Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. - Wikidata - wikimedia - TriplyDB

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.

http://www.wikidata.org/entity/Q34641796

about

Ivabradine as adjuvant treatment for chronic heart failure Ivabradine as adjuvant treatment for chronic heart failure Recent advances in treatment of heart failure Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more.Risk-benefit assessment of ivabradine in the treatment of chronic heart failure Early remodeling of perinuclear Ca2+ stores and nucleoplasmic Ca2+ signaling during the development of hypertrophy and heart failure.Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.Long-Term Prognostic Risk in Lower Extremity Peripheral Arterial Disease as a Function of the Number of Peripheral Arterial Lesions Heart failure in elderly: progress in clinical evaluation and therapeutic approach.Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model.Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.Medication management of chronic heart failure in older adults.Antiarrhythmic drugs 2013: state of the art.Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.Ivabradine.Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure.Ivabradine for the treatment of chronic heart failure.Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.Rationales and choices for the treatment of patients with NYHA class II heart failure.Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults.Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.Predictors of Long-Term Mortality and Frequent Re-Hospitalization in Patients with Acute Decompensated Heart Failure and Kidney Dysfunction Treated with Renin-Angiotensin System Blockers.Ivabradine in heart failure: hope or hype?Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study).Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study.Multimorbidity in heart failure patients.Lessons learned in acute heart failure.Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine.[Acute and chronic heart failure in light of the new ESC guidelines].Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?

P2860

Q24185982-9229B86E-F9DE-4A3D-A810-23DEE73712BC Q24201614-2F925633-C641-4777-AD6E-7154E2DF1DF3 Q26766223-6E94776F-3BAC-438A-982A-6B9A746EEBCA Q26773370-703554DE-6722-497E-9F95-08FB4D9B1D84 Q30573351-A5A21015-FB8F-4CAE-8D5A-317A772BEB2F Q33568592-760C87A6-2DCF-4109-A1ED-E64562235A72 Q33911390-987F14AA-35EB-4C1E-8E8C-82C00FC39DFA Q34041875-2BFC0A38-CF9C-4650-9851-1BFE8BF4A666 Q36770945-A0702BAF-1D6E-4588-B77C-1F3E70CFC65A Q36836008-F5DB2774-E1F0-4BB4-BF39-46898EBF3907 Q37001576-A186C178-5E26-4C6A-87B4-6B87D163DBF9 Q37248454-62F1EED1-35C7-427B-826E-0D39A244E86A Q38062592-9157DAB5-B3FF-4699-B9C7-BBB75A654983 Q38126374-BDF5AF0A-FA82-4EE1-B80D-059AF2D8BE9C Q38139281-13FF9561-9BC8-4CC4-8945-DC7567B102B0 Q38142792-BB981881-6113-4774-AD87-EDC80F413777 Q38174653-362F3E05-4EC7-4022-A170-0CC3D3003F84 Q38546359-729A6E61-3085-4C75-A112-10C99C5C9253 Q38621386-975F51BF-629A-4008-B153-E0FBD3E735B2 Q38769814-9986CD44-D00B-4B1F-BE3C-C0D4AFE76B40 Q38806549-F8C9E6AB-07C1-4074-B71B-FD5A069EEC34 Q39410727-7CE9B130-D474-44A2-8EF3-33790E6B102F Q39981333-41BC6F1E-25BB-424E-BC48-BA20468DA660 Q40544844-16B7E773-C4E8-4691-ADE0-5D3EE31F3B42 Q40549451-4982F8E7-0763-45C9-B735-C28384B7B374 Q41045555-81EBC64A-B7CA-4F40-BD1B-8EE793DC859B Q42697471-CBD0FC6D-E549-4A58-ABB2-D0C2722CD3D4 Q45987253-7AE55FBC-4840-4693-A3B6-C59C03B14CCA Q48671978-52F78459-0987-4F7E-A940-3E1B2FFE7C38 Q50089576-85A31628-C621-4713-99FF-6253F768C030 Q52994251-D7B741F6-5F36-42DF-A104-1E0E412F202D Q53606397-0B3F60C0-3EEF-48AE-89F8-2FFB0EB400A7 Q53637670-796BD1F8-B5DA-409C-BD46-DB37BDD00C65 Q54716857-32A4707A-2602-48FD-B054-0DEFD4DFDB59 Q57396219-8CFF2312-5702-48D7-9EAA-24DBA342FC35

P2860

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.

http://www.wikidata.org/entity/Q34641796

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@ast

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@en

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@nl

type

label

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@ast

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@en

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@nl

prefLabel

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@ast

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@en

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@nl

P1433

Q34641796-2A397C18-989B-44E3-81D0-878422201198

P1476

Q34641796-39C9FF7C-6323-4966-AD14-CFB47FF7CA35

P2093

Q34641796-03DD44DD-BD81-4B4E-BA68-BD410CD9FDED

Q34641796-2469FA7F-F00A-4C91-9B10-8D33611DD9B5

Q34641796-31FC277E-B5C3-4106-9989-7EBE58F3C9FA

Q34641796-4C388DF5-1B78-416B-A6E7-60BEB3C24468

Q34641796-76ED4B64-D455-4372-9A5C-E8BF7DC34F44

Q34641796-CBAED22A-AFDF-497E-8E28-D7EFFFE414ED

Q34641796-FBDF6C9C-DC3C-4180-9DF2-7DB1D28A8C1D

P2860

Q34641796-0023CA9C-E1B0-4A13-88B4-F54D76BA3C04

Q34641796-0423CB17-A8CE-4CE7-A34D-F3FBADBB7DDB

Q34641796-0E1BFD85-FD91-4A22-874B-8D499EDB80F3

Q34641796-18C0C591-033C-4310-AE8D-891BE2FAE809

Q34641796-1AAC1A1D-4564-4EF3-B7B8-21A4B2EFF7A6

Q34641796-1BBA26C0-B8D9-4A72-A850-9D6EBC53AA9D

Q34641796-262A846D-001A-48BE-BDBD-3C6B23CCC3C6

Q34641796-67CDA517-7A18-4F3A-AC05-6A107AB3E8B1

Q34641796-7C6C8597-F643-421F-B0A9-AF2D2C81311E

Q34641796-87AF4292-92AC-47B6-BBC4-CAA2A1CF81A7

P304

Q34641796-F8E8366B-0AE5-461F-9580-CA212F8DD804

P31

Q34641796-CE30CA88-090F-4209-ACBF-A7A557A730F1

P356

Q34641796-9CC5B9D6-ACFA-40D2-A3A5-9D146F0A9220

P433

Q34641796-A395B916-3567-401A-A9B6-9604B56630C9

P478

Q34641796-17EC1717-FE77-4916-B66E-0B36D3848CF8

P50

Q34641796-2B03E18B-AC8F-4E67-B38D-E4DE84086FA7

Q34641796-7FBC8A6A-D042-49A0-920E-D6D607A45C74

Q34641796-E8946F7A-DBCD-4F0E-AEBB-0A6FE9294F91

P577

Q34641796-C37395CC-AA98-4A60-B356-F829431B6F0F

P5875

Q34641796-1273CE11-38E4-4070-AA19-5681A6E9481A

P698

Q34641796-A050B49A-DF71-476A-994E-21CB8C1708E2

P921

Q34641796-18A16AD2-FAAF-42F5-AEF4-0F5E1B1D6878

Q34641796-38E60697-A75C-4930-A90E-C03AC645EEC6

Q34641796-C1E24AB0-1816-49B9-9AD9-86F810A56E95

Q34641796-EA23C27F-0D3A-4D87-9771-A083F7A90B5D

P932

Q34641796-E88E45EA-68CB-4EB9-8BE4-E6155F2902A1

P356

P1433

European Heart Journal

P1476

Effect of ivabradine on recurr ...... eart failure: the SHIFT Study.

@en

P2093

Esteban Lopez-de-Sa

http://www.w3.org/2001/XMLSchema#string

Ian Ford

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Borer

http://www.w3.org/2001/XMLSchema#string

Jose Lopez Sendon

http://www.w3.org/2001/XMLSchema#string

Marco Alings

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

SHIFT Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Hospitalizations after heart failure diagnosis a community perspective.

The current cost of heart failure to the National Health Service in the UK.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008

Economic burden of heart failure in the elderly.

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).

Hospitalizations for heart failure in the United States--a sign of hope.

P304

2813-2820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHS259

http://www.w3.org/2001/XMLSchema#string

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230749103

http://www.w3.org/2001/XMLSchema#string

P698

22927555

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

3498004

http://www.w3.org/2001/XMLSchema#string